Article Text

Download PDFPDF

Correspondence response
Response to: ‘Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?’ by Nocturne et al
  1. Louise K Mercer1,
  2. James B Galloway2,
  3. Mark Lunt1,
  4. Rebecca Davies1,
  5. Audrey AL Low1,
  6. Will G Dixon1,2,
  7. Kath D Watson1,
  8. Deborah PM Symmons1,2,
  9. Kimme L Hyrich1,2
  1. 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, UK
  2. 2King's College London, London, UK
  1. Correspondence to Professor Kimme L Hyrich, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; kimme.hyrich{at}

Statistics from

We thank Nocturne et al1 for their interest and comments on our recent paper, which looked at lymphoma risk over the medium term in a cohort of patients receiving tumour necrosis factor inhibitor (TNFi).1 Overall we found no statistically significant difference in the risk compared with conventional standard disease-modifying antirheumatic drugs (csDMARDs) either for all TNFi exposures combined or when each TNFi was analysed separately in comparison to csDMARDs, using a number of different models to categorise treatment exposure.

We agree that lymphoma is a heterogeneous group of malignancies and that the spectrum of lymphomas seen in people with rheumatoid arthritis (RA) is different from that in the general population, with an over-representation of inflammation-driven diffuse large B-cell lymphoma (DLBCL). Therefore, understanding whether TNFi treatment is associated with an increase in the risk …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles